SavedAdd your journal

Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2006 / Cilt: 52 - Sayı: 4

The ratio of second-line drug usage time to disease duration and reasons for drug cessation in rheumatoid arthritis patients

Romatoid artritli hastalarda ikinci basamak ilaç kullanım sürelerinin toplam hastalık sürelerine oranları ve ilaçların kesilme nedenleri

Aytül ÇAKCI
Emel EKŞİOĞLU
Beyhan TUNCAY
Eda GÜRÇAY
Pages
158–162
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Drugs having maximum efficacy and minimum side effects are still needed in rheumatoid arthritis treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim in the treatment of rheumatoid arthritis (RA) is to reduce disability and articular destruction to a minimum with the help of disease modifying anti-rheumatic drugs (DMARDs).
📊
Key Findings & Data:The side effects and reasons for drug cessation were investigated in 85 RA patients.
💡
Conclusion & Impact:Conclusion: Drugs having maximum efficacy and minimum side effects are still needed in rheumatoid arthritis treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim in the treatment of rheumatoid arthritis (RA) is to reduce disability and articular destruction to a minimum with the help of disease modifying anti-rheumatic drugs (DMARDs). However, their efficacy and side effects profile may limit the usage of these drugs. Materials and Methods: In this study, DMARDs usage ratio was calculated by dividing total drug usage time (month) by disease duration (month). The side effects and reasons for drug cessation were investigated in 85 RA patients. Results: Sulfasalazine was determined as the drug used for the longest period (27%) during the disease duration. Sulfasalazine and antimalarial drugs were stopped for their ineffectiveness at rates of 35.7% and 47.8%, respectively. Methotrexate was stopped for gastrointestinal intolerance (36.4%), cyclosporin for nephrotoxicity (71.4%), leflunomide for hematologic side effects and hepatotoxicity (37.5%), and gold salts due to unavailability (70.8%). Conclusion: Drugs having maximum efficacy and minimum side effects are still needed in rheumatoid arthritis treatment.

Özet

Amaç: Romatoid artritli (RA) hastalarda tedavideki amaç hastalık aktivitesini kontrol altına almaya yönelik ilaçları (DMARD) kullanarak eklem hasarını ve özürlülüğü minimuma indirmektir. Ancak bu ilaçların etki ve yan etki profilleri ilaç kullanımını sınırlandırabilmektedir. Gereç ve Yöntem: Bu çalışmada 85 RA'lı hastanın DMARD kullanma oranı, ilaç kullanma süresinin (ay) toplam hastalık süresine (ay) bölünmesiyle % (yüzde) olarak hesaplanmış; ilaçların yan etkileri ve ilaç kesilme nedenleri sorgulanmıştır. Bulgular: Hastalık süresince en uzun kullanılan ilaç sulfasalazin (%27) olarak bulunmuştur. Sülfasalazin ve antimalaryaller en fazla etkisizlik (sırasıyla %35,7, %47,8), metotreksat gastrointestinal intoleransı (%36,4), siklosporin nefrotoksisite (%71,4), leflunomid hematolojik yan etki ve hepatotoksisite (%37,5), altın preperatları yeni ilaçların çıkması (%70,8) nedeniyle kesilmiştir. Sonuç: RA tedavisinde etkinin maksimum, yan etkinin minimum olduğu ilaçlara halen ihtiyaç duyulmaktadır.

🔖

Cite This Article

ÇAKCI, A., EKŞİOĞLU, E., TUNCAY, B., GÜRÇAY, E. (2022). The ratio of second-line drug usage time to disease duration and reasons for drug cessation in rheumatoid arthritis patients. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 52 - Sayı: 4, 158–162. https://ajindex.com/articles/629190

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Zvaifler NJ. Etiology and pathogenesis of Rheumatoid Arthritis. In: McCarty DJ, Koopman WJ, editors. Arthritis & Allied Conditions. 12th ed. Philadelphia: Lea & Febiger; 1993. p. 723-36
  2. Fuchs HA, Sergent JS. Rheumatoid Arthritis: The Clinical Picture. In: Koopman WJ, editor. Arthritis & Allied Conditions. 13th ed. Pennsylvania: Williams & Wilkins; 1997. p. 1041-70
  3. Harris ED. Clinical Features of Rheumatoid Arthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of Rheumatology. 4th ed. Philadelphia: WD, Saunders; 1993. p. 874-911
  4. Ergin S. Romatoid Artrit ve Sjögren Sendromu. Beyazova M, Gökçe Kutsal Y, editörler. Fiziksel T›p ve Rehabilitasyon. 1. bas›m. Ankara: Günefl Kitabevi; 2000. s. 1549-76
  5. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis 2002 update. Arthritis Rheum 2002;46:328-46
  6. O'Dell JR. Treating strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602
  7. Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE. Patient, disease, and theraphy-related factors that influence discontinuation of disease modifying antirheumatic drugs: a population-based incidance cohort of patients with rheumatoid arthritis. J Rheumatol 2006;33:248-55
  8. Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a long-term observational study. J Rheumatol 2002;29:261-6
  9. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
  10. Mundo A, Pedone V, Lamanna G, Cervini C. Sulfasalazine: Side effect and duration of therapy in patients with rheumatoid arthritis. Clin Ther 1997;148:7-13
  11. Jones E, Jones JV, Woodbury JFL. Response to sulphasalazine in rheumatoid arthritis: Life table analysis of a 5-year follow up. J Rheumatol 1991;18:195-8
  12. Porter DR, Mclnnes I, Hunter J, Capell HA. Outcome of second line theraphy in rheumatoid arthritis. Ann Rheum Dis 1994;53:812-5
  13. Wijnands MJ, van't Hof MA, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Long term second line treatment: a prospective drug survival study. Br J Rheumatol 1992;31:253-8
  14. Keysser M, KeyBer G, Keysser C. Long term application of disease modifying antirheumatic drugs (DMARD). A single-center, observational study of 1681 patients with rhe